Sunstone Therapies logo.jpg
Sunstone Therapies to participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
20 juin 2024 07h00 HE | Sunstone Therapies
Sunstone Therapies to participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference Rockville, Maryland, June 20, 2024 – Sunstone Therapies, a leader in the delivery of...
NEW ATAI-Logo_Primary.png
atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference
31 mai 2024 07h00 HE | atai Life Sciences
NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental...
OptimiTM-03.jpg
Optimi Health Secures Import Permit from Mind Medicine Australia for MDMA and Psilocybin Capsules
29 mai 2024 08h00 HE | Optimi Health Corp.
Optimi Health preparing to export 160 doses of MDMA and psilocybin under Australia’s Authorized Prescriber Scheme.
NEW ATAI-Logo_Primary.png
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
23 mai 2024 07h00 HE | atai Life Sciences
NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental...
TM-Logo-Navy.png
Novotech Announces MOU with Experienced Psychedelics Research Center at the 4th Annual Psychedelic Therapeutics and Drug Development Conference in Boston
22 mai 2024 20h11 HE | Novotech
Novotech Announces MOU with Experienced Psychedelics Research Center at the 4th Annual Psychedelic Therapeutics and Drug Development Conference in Boston
OptimiTM-03.jpg
Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder
22 mai 2024 08h30 HE | Optimi Health Corp.
Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder
NEW ATAI-Logo_Primary.png
atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
15 mai 2024 06h59 HE | atai Life Sciences
First participant dosed in Phase 1b trial of VLS-01 with data expected in 2H’24; Phase 2 study in TRD patients anticipated to initiate around YE’24Beckley Psytech’s Phase 2a study of BPL-003 in TRD...
OptimiTM-03.jpg
Optimi Health Receives Certificate of Analysis For MDMA 40mg and 60mg GMP Capsules
14 mai 2024 08h00 HE | Optimi Health Corp.
Optimi Health Receives Certificate of Analysis For GMP MDMA 40mg and 60mg MDMA Capsules.
OptimiTM-03.jpg
Optimi Health Provides Corporate Update
10 mai 2024 08h50 HE | Optimi Health Corp.
Optimi Health provides corporate update.
OptimiTM-03.jpg
Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University's Institute for Psychedelic Research
09 mai 2024 08h00 HE | Optimi Health Corp.
Export Permit granted: Optimi's Shipment of MDMA active pharmaceutical ingredient (API) to Israel marks the Company’s first international export